We serve Chemical Name:4-bromo-N,N-diethyl-2-fluorobenzamide CAS:682778-07-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-bromo-N,N-diethyl-2-fluorobenzamide
CAS.NO:682778-07-0
Synonyms:N,N-diethyl-2-fluoro-4-bromobenzamide;4-bromo-N,N-diethyl-2-fluoro-benzamide
Molecular Formula:C11H13BrFNO
Molecular Weight:274.12900
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:20.31000
Exact Mass:273.01600
LogP:3.07020
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N,N-diethyl-2-fluoro-4-bromobenzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-N,N-diethyl-2-fluoro-benzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-N,N-diethyl-2-fluoro-benzamide Use and application,N,N-diethyl-2-fluoro-4-bromobenzamide technical grade,usp/ep/jp grade.
Related News: Wuhan officials estimate about 5 million people had left the city for the annual Lunar New Year holiday before authorities canceled all outbound flights, trains and buses in an unprecedented lockdown on January 23. 4-bromo-N,N-diethyl-2-fluorobenzamide manufacturer The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. 4-bromo-N,N-diethyl-2-fluorobenzamide supplier In October 2020, the Trump administration ordered $375 million worth of Lilly’s COVID-19 antibody therapy bamlanivimab, which is manufactured at the Branchburg plant. 4-bromo-N,N-diethyl-2-fluorobenzamide vendor Wuhan officials estimate about 5 million people had left the city for the annual Lunar New Year holiday before authorities canceled all outbound flights, trains and buses in an unprecedented lockdown on January 23. 4-bromo-N,N-diethyl-2-fluorobenzamide factory The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.
